ApoA1 can also be analyzed with neutrophils, forming a neutrophil-to-ApoA1 ratio (NAR), which can predict the overall survival of HCC patients treated with transarterial chemoembolization (Chen et al., 2021). This evidence concerns the gene APOA1 and hepatocellular carcinoma.